Trials / Completed
CompletedNCT00280397
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerable dose (MTD) and the related effects of E7080 administered to patients with solid tumors that are resistant to approved existing anti-tumor therapies, or for which no appropriate treatment is available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7080 | E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available. |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-09-01
- Completion
- 2008-11-01
- First posted
- 2006-01-23
- Last updated
- 2016-10-07
- Results posted
- 2015-03-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00280397. Inclusion in this directory is not an endorsement.